{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:07:07Z","timestamp":1789495627270,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004704","name":"the National Research Council of Thailand","doi-asserted-by":"crossref","award":["N41A660172"],"award-info":[{"award-number":["N41A660172"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004704","name":"the National Research Council of Thailand","doi-asserted-by":"crossref","award":["N34E670096"],"award-info":[{"award-number":["N34E670096"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship, Chulalongkorn University"},{"name":"Ratchadapiseksompotch Fund Chulalongkorn University","award":["RCU_68_006_3300_001"],"award-info":[{"award-number":["RCU_68_006_3300_001"]}]},{"name":"Center of Excellence on Medical Biotechnology (CEMB), The S&T Postgraduate Education and Research Development Office (PERDO), The Commission on Higher Education (CHE), Thailand."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49988-w","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:27:53Z","timestamp":1776806873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MUC1-targeted CAR-T cell secreted anti-PD-1 IgG antibody enhances antitumor activity in Cholangiocarcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Nattarika","family":"Khuisangeam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyavi","family":"Chinsuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thananya","family":"Intanachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rattapoom","family":"Thaiwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatikorn","family":"Boonkrai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanapati","family":"Phakham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trairak","family":"Pisitkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koramit","family":"Suppipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattiya","family":"Hirankarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supannikar","family":"Tawinwung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"1","key":"49988_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. Cancer J. Clin. 70 (1), 7\u201330 (2020).","journal-title":"Cancer J. Clin."},{"issue":"9","key":"49988_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Reviews Gastroenterol. Hepatol. 17 (9), 557\u2013588 (2020).","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"key":"49988_CR3","doi-asserted-by":"crossref","unstructured":"Espinoza, J. L. Fluke-related cholangiocarcinoma: challenges and opportunities. Pathogens 12 (12), 1429 (2023).","DOI":"10.3390\/pathogens12121429"},{"issue":"5","key":"49988_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales, J. M. et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Reviews Gastroenterol. Hepatol. 13 (5), 261\u2013280 (2016).","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"issue":"3","key":"49988_CR5","first-page":"285","volume":"19","author":"F Mihalache","year":"2010","unstructured":"Mihalache, F. et al. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J. Gastrointestin Liver Dis. 19 (3), 285\u2013290 (2010).","journal-title":"J. Gastrointestin Liver Dis."},{"issue":"1","key":"49988_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s12885-021-08247-z","volume":"21","author":"C Tawarungruang","year":"2021","unstructured":"Tawarungruang, C. et al. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification. BMC Cancer. 21 (1), 497 (2021).","journal-title":"BMC Cancer"},{"issue":"2","key":"49988_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.7314\/APJCP.2013.14.2.1107","volume":"14","author":"S Sriputtha","year":"2013","unstructured":"Sriputtha, S. et al. Survival rate of intrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. Asian Pac. J. Cancer Prev. 14 (2), 1107\u20131110 (2013).","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"49988_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao, Z. et al. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm. Sin B. 8 (4), 539\u2013551 (2018).","journal-title":"Acta Pharm. Sin B"},{"issue":"1","key":"49988_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1477-7827-2-4","volume":"2","author":"M Brayman","year":"2004","unstructured":"Brayman, M., Thathiah, A. & Carson, D. D. MUC1: A multifunctional cell surface component of reproductive tissue epithelia. Reproductive Biology Endocrinol. 2 (1), 4 (2004).","journal-title":"Reproductive Biology Endocrinol."},{"key":"49988_CR10","doi-asserted-by":"crossref","unstructured":"Chen, W. et al. MUC1: structure, function, and clinic application in epithelial cancers. Int. J. Mol. Sci. 22 (12), 6567 (2021).","DOI":"10.3390\/ijms22126567"},{"issue":"32","key":"49988_CR11","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.3748\/wjg.v11.i32.4939","volume":"11","author":"C Boonla","year":"2005","unstructured":"Boonla, C. et al. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J. Gastroenterol. 11 (32), 4939\u20134946 (2005).","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"49988_CR12","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/hep.510300609","volume":"30","author":"M Higashi","year":"1999","unstructured":"Higashi, M. et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 30 (6), 1347\u20131355 (1999).","journal-title":"Hepatology"},{"issue":"5","key":"49988_CR13","first-page":"1333","volume":"7","author":"T Kawamoto","year":"2001","unstructured":"Kawamoto, T. et al. Expression of MUC1 mucins in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Clin. Cancer Res. 7 (5), 1333\u20131342 (2001).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"49988_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4161\/cam.23131","volume":"7","author":"TM Horm","year":"2013","unstructured":"Horm, T. M. & Schroeder, J. A. MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell. Adh Migr. 7 (2), 187\u2013198 (2013).","journal-title":"Cell. Adh Migr."},{"key":"49988_CR15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","volume":"10","author":"R Zhou","year":"2019","unstructured":"Zhou, R. et al. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth. Front. Immunol. 10, 1149 (2019).","journal-title":"Front. Immunol."},{"issue":"1","key":"49988_CR16","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41598-021-85747-9","volume":"11","author":"K Supimon","year":"2021","unstructured":"Supimon, K. et al. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Sci. Rep. 11 (1), 6276 (2021).","journal-title":"Sci. Rep."},{"issue":"2","key":"49988_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jcyt.2022.10.006","volume":"25","author":"K Supimon","year":"2023","unstructured":"Supimon, K. et al. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells. Cytotherapy 25 (2), 148\u2013161 (2023).","journal-title":"Cytotherapy"},{"issue":"1","key":"49988_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi, F. et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res. Ther. 12 (1), 81 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"49988_CR19","doi-asserted-by":"crossref","unstructured":"Barriga, V. et al. The complex interaction between the tumor micro-environment and immune checkpoints in breast cancer. Cancers (Basel) 11 (8), 1205 (2019).","DOI":"10.3390\/cancers11081205"},{"issue":"15","key":"49988_CR20","doi-asserted-by":"publisher","first-page":"24644","DOI":"10.18632\/oncotarget.15602","volume":"8","author":"J Fontugne","year":"2017","unstructured":"Fontugne, J. et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 8 (15), 24644\u201324651 (2017).","journal-title":"Oncotarget"},{"issue":"8","key":"49988_CR21","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 1 (8), EVIDoa2200015 (2022).","journal-title":"NEJM Evid."},{"issue":"10391","key":"49988_CR22","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401 (10391), 1853\u20131865 (2023).","journal-title":"Lancet"},{"issue":"6","key":"49988_CR23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen, A. M. et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22 (6), 1211\u20131220 (2014).","journal-title":"Mol. Ther."},{"key":"49988_CR24","doi-asserted-by":"publisher","first-page":"p2449373","DOI":"10.1155\/2022\/2449373","volume":"2022","author":"N Khuisangeam","year":"2022","unstructured":"Khuisangeam, N. et al. An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment. J. Immunol. Res. 2022, p2449373 (2022).","journal-title":"J. Immunol. Res."},{"issue":"5","key":"49988_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2 (5), 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"issue":"2","key":"49988_CR26","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/cam4.2733","volume":"9","author":"Z Mei","year":"2020","unstructured":"Mei, Z. et al. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma. Cancer Med. 9 (2), 640\u2013652 (2020).","journal-title":"Cancer Med."},{"issue":"11","key":"49988_CR27","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/0008-5472.CAN-09-0564","volume":"69","author":"J Maher","year":"2009","unstructured":"Maher, J. & Wilkie, S. CAR Mechanics: Driving T Cells into the MUC of Cancer. Cancer Res. 69 (11), 4559\u20134562 (2009).","journal-title":"Cancer Res."},{"issue":"7","key":"49988_CR28","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie, S. et al. Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor1. J. Immunol. 180 (7), 4901\u20134909 (2008).","journal-title":"J. Immunol."},{"issue":"2","key":"49988_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1245\/s10434-019-07701-4","volume":"27","author":"Y Kitano","year":"2020","unstructured":"Kitano, Y. et al. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients. Ann. Surg. Oncol. 27 (2), 599\u2013607 (2020).","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"49988_CR30","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","volume":"15","author":"I Andreu-Saumell","year":"2024","unstructured":"Andreu-Saumell, I. et al. CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition. Nat. Commun. 15 (1), 3552 (2024).","journal-title":"Nat. Commun."},{"issue":"2","key":"49988_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey, J. D. & Zhang, B. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J. 23 (2), 39 (2021).","journal-title":"AAPS J."},{"issue":"1","key":"49988_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13058-022-01531-1","volume":"24","author":"M Harrasser","year":"2022","unstructured":"Harrasser, M. et al. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC. Breast Cancer Res. 24 (1), 39 (2022).","journal-title":"Breast Cancer Res."},{"key":"49988_CR33","doi-asserted-by":"publisher","first-page":"106196","DOI":"10.1016\/j.pep.2022.106196","volume":"202","author":"J Shin","year":"2023","unstructured":"Shin, J. et al. Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells. Protein Exp. Purif. 202, 106196 (2023).","journal-title":"Protein Exp. Purif."},{"issue":"9","key":"49988_CR34","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","volume":"14","author":"A Kitchlu","year":"2021","unstructured":"Kitchlu, A. et al. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin. Kidney J. 14 (9), 2012\u20132022 (2021).","journal-title":"Clin. Kidney J."},{"key":"49988_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","volume":"91","author":"JT Sockolosky","year":"2015","unstructured":"Sockolosky, J. T. & Szoka, F. C. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv. Drug Deliv Rev. 91, 109\u2013124 (2015).","journal-title":"Adv. Drug Deliv Rev."},{"issue":"7","key":"49988_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik, M. et al. The therapeutic age of the neonatal Fc receptor. Nat. Rev. Immunol. 23 (7), 415\u2013432 (2023).","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"49988_CR37","first-page":"225","volume":"42","author":"D Colcher","year":"1998","unstructured":"Colcher, D. et al. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q. J. Nucl. Med. 42 (4), 225\u2013241 (1998).","journal-title":"Q. J. Nucl. Med."},{"key":"49988_CR38","doi-asserted-by":"crossref","unstructured":"Joo, V. et al. A CD64\/Fc\u03b3RI-mediated mechanism hijacks PD-1 from PD-L1\/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells. Front. Immunol. 14, 121375 (2023).","DOI":"10.3389\/fimmu.2023.1213375"},{"issue":"11","key":"49988_CR39","doi-asserted-by":"publisher","first-page":"114907","DOI":"10.1016\/j.celrep.2024.114907","volume":"43","author":"E Ben Saad","year":"2024","unstructured":"Ben Saad, E. et al. PD-1 endocytosis unleashes the cytolytic potential of checkpoint blockade in tumor immunity. Cell. Rep. 43 (11), 114907 (2024).","journal-title":"Cell. Rep."},{"key":"49988_CR40","doi-asserted-by":"publisher","first-page":"1383456","DOI":"10.3389\/fimmu.2024.1383456","volume":"15","author":"SA Javed","year":"2024","unstructured":"Javed, S. A. et al. Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges. Front. Immunol. 15, 1383456 (2024).","journal-title":"Front. Immunol."},{"issue":"23","key":"49988_CR41","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","volume":"7","author":"ER Suarez","year":"2016","unstructured":"Suarez, E. R. et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget 7 (23), 34341\u201334355 (2016).","journal-title":"Oncotarget"},{"issue":"9","key":"49988_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36 (9), 847\u2013856 (2018).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"49988_CR43","doi-asserted-by":"publisher","first-page":"e12688","DOI":"10.1016\/j.heliyon.2022.e12688","volume":"9","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105. Heliyon 9 (1), e12688 (2023).","journal-title":"Heliyon"},{"key":"49988_CR44","doi-asserted-by":"publisher","first-page":"114970","DOI":"10.1016\/j.bcp.2022.114970","volume":"198","author":"Q Xin","year":"2022","unstructured":"Xin, Q. et al. Animal models of acute lymphoblastic leukemia: Recapitulating the human disease to evaluate drug efficacy and discover therapeutic targets. Biochem. Pharmacol. 198, 114970 (2022).","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"49988_CR45","first-page":"379","volume":"3","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Preclinical models for development of immune-oncology therapies. Immuno-oncol Insights. 3 (8), 379\u2013398 (2022).","journal-title":"Immuno-oncol Insights"},{"issue":"7","key":"49988_CR46","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1101\/pdb.top073585","volume":"2014","author":"LD Shultz","year":"2014","unstructured":"Shultz, L. D. et al. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc. 2014 (7), 694\u2013708 (2014).","journal-title":"Cold Spring Harb Protoc."},{"issue":"1","key":"49988_CR47","doi-asserted-by":"publisher","first-page":"152438","DOI":"10.1016\/j.seminoncol.2025.152438","volume":"53","author":"SI Mohammad","year":"2026","unstructured":"Mohammad, S. I. et al. Genome editing of immune checkpoints: CRISPR-mediated PD-1 inhibition in cancer. Semin Oncol. 53 (1), 152438 (2026).","journal-title":"Semin Oncol."},{"key":"49988_CR48","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367 (6481), p.eaba7365 (2020)."},{"issue":"8","key":"49988_CR49","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15 (8), 486\u2013499 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"49988_CR50","doi-asserted-by":"publisher","first-page":"101514","DOI":"10.1016\/j.tranon.2022.101514","volume":"25","author":"R Carloni","year":"2022","unstructured":"Carloni, R. et al. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine. Translational Oncol. 25, 101514 (2022).","journal-title":"Translational Oncol."},{"issue":"7","key":"49988_CR51","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2217\/imt-2016-0002","volume":"8","author":"C Kyi","year":"2016","unstructured":"Kyi, C. & Postow, M. A. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy 8 (7), 821\u2013837 (2016).","journal-title":"Immunotherapy"},{"issue":"1","key":"49988_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","volume":"12","author":"W Ma","year":"2023","unstructured":"Ma, W. et al. Increasing cure rates of solid tumors by immune checkpoint inhibitors. Experimental Hematol. Oncol. 12 (1), 10 (2023).","journal-title":"Experimental Hematol. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49988-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49988-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49988-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:31:02Z","timestamp":1781649062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49988-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49988"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49988-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18597"}}